Suchergebnisse - "Arthritis, Rheumatoid"

PubPharm (63)

1

Rheuma-Ampel : 2600 Lebensmittel bewertet

Erschienen: Stuttgart, TRIAS, 2021

Ampeln

3. Auflage

von Müller, S.

2

CADTH reimbursement recommendation : indication: rheumatoid arthritis : recommendation : reimburse with conditionsInfliximab SC (Remsima SC)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, April 2021

CADTH reimbursement review

Version: 1.0.

3

Clinical and economic review report : Celltrion Healthcare Co., Ltd. : indication : rheumatoid arthritisInfliximab SC (Remsima)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, August 2021

CADTH common drug review

Version: Final (with redactions).

4

Clinical review report : indication : for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexateUpadacitinib (Rinvoq) (AbbVie)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, March 2020

CADTH common drug review

5

Pharmacoeconomic review report : indication: for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexateUpadacitinib (Rinvoq) (AbbVie)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, March 2020

CADTH common drug review

Version: final.

6

CADTH Canadian drug expert committee recommendation : indication : for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexateUpadacitinib (Rinvoq -- abbVie)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, February 2020

CADTH common drug review

Version: 1.0.

7

Sagittales Alignment und Outcome nach atlantoaxialer Spondylodese bei rheumatischer Instabilität

Erschienen: Dissertation, Universität Ulm, 2021

von Catena, M.

8

Comparing two programs for helping patients make informed decisions about rheumatoid arthritis treatment

Erschienen: [Washington, D.C.], Patient-Centered Outcomes Research Institute (PCORI), [2020]

Final research report

von Blalock, S.

9

Pharmacoeconomic review report : (Eli Lilly Canada Inc.)Baricitinib (Olumiant)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, September 2019

CADTH common drug review

Version: final.

10

Clinical review report : (Eli Lilly Canada Inc.)Baricitinib (Olumiant)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, September 2019

CADTH common drug review

Version: final (with redactions).

1
2
3
4
5
6
7
Nächster »
[7]